Tvardi Therapeutics, Inc.TVRD
What Tvardi Therapeutics, Inc. does.
We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders ’ seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing.
Our pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is our first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance our ability to target STAT3. We have been developing TTI-109 for several years, based on our recognition that retaining the full STAT3 inhibition mechanism of TTI-101 while enhancing delivery would broaden the potential utility of our platform across inflammatory and proliferative indications. We filed an Investigational New Drug (IND) application for TTI-109 in June 2025 and, following FDA acceptance, initiated a Phase 1 trial in healthy volunteers evaluating safety, tolerability, pharmacokinetics, and bioequivalence to TTI-101. We expect to report topline data from this trial in the second quarter of 2026, after which we intend to announce the clinical indication in which we plan to advance TTI-109.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $135.1M | $23.0M | $41.9M | $21.0M | $7.1M | — |
| Net income | $8.4M | -$88.4M | -$85.5M | -$118.5M | -$29.4M | -$18.2M |
| Free cash flow | -$5.8M | -$60.1M | -$78.8M | -$94.5M | -$19.4M | — |
More on TVRD.
- Tvardi Therapeutics, Inc. summary
- Tvardi Therapeutics, Inc. financial statements
- Tvardi Therapeutics, Inc. key metrics
- Tvardi Therapeutics, Inc. health scores and style box
- Tvardi Therapeutics, Inc. earnings
- Tvardi Therapeutics, Inc. dividends
- Tvardi Therapeutics, Inc. valuation
- Tvardi Therapeutics, Inc. ownership and insiders
- Tvardi Therapeutics, Inc. peers
Figures from Tvardi Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.